Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

Table 3 Cost estimates for cost-effectiveness analysis of NAC and AC

Event	NAC	AC	Source
Surgery^a	2351.96	2367.82	MPFS [30]
Additional surgical procedures^a	1854.46	2513.65	MPFS [30]
Hospitalization
With ≥ 3 complication	96,462	96,462	Xin et al. [27]
Without ≥ 3 complication	66,800	66,800	Xin et al. [27]
Chemotherapy (4 cycles)	30,946.5	30,946.5	Local charge [30]
Imaging	6036	3568	Local charge [30]
≥ 3 grade chemotherapy adverse event treatment^b	3679.8	3679.8	CTCAE [28] CSCO [29]

^aCost was calculated as the weighted average of results reported in Brandt et al. [10]; see Additional file 1: Table S1 for individual procedures and probabilities
^bCost was calculated as the weighted average of results reported in NATCH [3]; see Additional file 2: Table S2 for individual procedures and probabilities

ISSN: 1478-7547